Nephrology

Last updated February 10, 2005

Saturday, MAY 14

8:00am–9:45am
4080A—Chronic Kidney Disease
ASPN Workshop
Chairs: Bradley A. Warady, Children's Mercy Hospital and Clinics, Kansas City, MO; and Victoria Norwood, University of Virginia Children's Medical Center, Charlottesville, VA

The optimal management of children with chronic kidney disease (CKD) requires attention to a multitude of clinical issues. However, information on the manifestations of CKD in children and their evolution with the progression of renal insufficiency is, in large part, anecdotal in nature. This session will be dedicated to a review of important aspects of the recently initiated Chronic Kidney Disease in Children (CKiD) study designed to provide long awaited data on pediatric CKD. The session will begin with an overview of the entire study and the progress that has been made in patient enrollment and data collection. This will be followed by presentations on approaches to the measurement of glomerular filtration rate (GFR), new and old, and the health-related quality of life (HRQOL) assessment in children with chronic illness. The final presentation will review the growing body of data on cardiovascular disease in children with CKD and the importance of cardiac-related investigations in this N.I.H. supported endeavor.

Target Audience: Pediatric nephrologists

CKiD: State of the Study
Bradley A. Warady, Children's Mercy Hospital and Clinics, Kansas City, MO

CKiD: State of the Study
Susan L. Furth, Johns Hopkins University School of Medicine, Baltimore, MD

Measurement of Glomerular Filtration Rate in Children: Historical and New Approaches
George J. Schwartz, Golisano Children's Hospital at Strong, Rochester, NY

Health-Related Quality of Life in Children with Chronic Conditions
James W. Varni, Texas A&M University, College Station, TX

Cardiovascular Disease in Children with Chronic Kidney Disease: Hidden Reality
Mark Mitsnefes, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Supported by the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
 

10:00am–12:00pm
4300—Development of Hypertension in the Newborn: Translating Theory into Practical Application
PAS/IPHA Topic Symposium
Chairs: Elaine Urbina, Children's Hospital Medical Center, Cincinnati, OH; and Luc Brion, Montefiore Medical Center, Bronx, NY

Hypertension is found in up to 2% of term or preterm neonates. The prevalence is difficult to ascertain precisely since the definition of hypertension in this age group has not been completely standardized. However, recent studies have provided normative data that may be useful in identifying these infants. This symposium will examine key aspects of the diagnosis of hypertension in the neonate including measurement and instrumentation issues and normal values. Pre- and post-natal risk factors for the development of neonatal hypertension will be addressed along with treatment options. Perinatal programming for future cardiovascular disease will also be addressed.

Target Audience: Neonatologists, pediatric nephrologists, pediatric cardiologists, general pediatricians

How Do We Measure BP in the Neonate and What Is Normal?
Alan Zubrow, Drexel University College of Medicine, St. Christopher's Hospital for Children, Philadelphia, PA

How Does “Perinatal Programming” Contribute to the Development of Subsequent Vascular Disease?
Julie R. Ingelfinger, Massachusetts General Hospital, Boston, MA

Perinatal Influences on Blood Pressure In the Newborn
Matthew W. Gillman, Harvard Medical School/Harvard Pilgrim Health Care, Boston, MA

What Non-pharmacologic and Drug Treatment Options Are Available for the Management of Neonatal Hypertension
Douglas L. Blowey, Children's Mercy Hospitals and Clinics, Kansas City, MO

Sponsored jointly by the International Pediatric Hypertension Association and the Pediatric Academic Societies
 

1:00pm–3:00pm
4600A—Urolithiasis and Mineral Metabolism
ASPN Symposium
Chairs: Uri S. Alon, Children's Mercy Hospital, Kansas City, MO; and Dawn S. Milliner, Mayo Clinic, Rochester, MN

The symposium will address new findings and developments in our understanding of phosphate homeostasis in health and disease. Genetic, environmental and idopathic etiologies of pediatric urolithiasis will be discussed, as well as medical means and urological techniques utilized in the management of kidney stone disease.

Target Audience: Scientists and clinicians involved with pediatric mineral metabolism and kidney stone disease.

New Insights into the Regulation of Phosphate Metabolism
Anthony A. Portale, University of California, San Francisco, CA

Pediatric Clinical Trials with Intravenous Vitamin D Analogs
Laurence Greenbaum, Medical College of Wisconsin, Milwaukee, WI

Genetic Basis of Stone Forming Disease
Dawn S. Milliner, Mayo Clinic, Rochester, MN

Idiopathic Calcium Stones
Uri S. Alon, Children's Mercy Hospital, Kansas City, MO

Discussion

Urologic Intervention in Children with Urolithiasis
Jeffrey S. Palmer, Rainbow Babies and Children's Hospital, Cleveland, OH
 

3:15pm–5:15pm
4850—Nephrology/Hypertension
PAS/ASPN Original Science Abstracts - Platform Session

5:15pm–7:15pm
Poster Session I
PAS Original Science Abstracts - Poster Session

Nephrology:
4940—Dialysis
4941—Hypertension
4942—Chronic Kidney Disease
4943—Obstruction/Development
4944—Tubular Disorders/Tubular Injury
4945—Clinical
 

8:00pm–10:00pm
4995A—ASPN Member Reception (ASPN)
ASPN Reception

Sunday, MAY 15

7:00am–8:00am
5056—Nephrology
Balancing Life as a Pediatric Nephrologist—Peeretty Great
PAS Meet the Professor Breakfast

F. Bruder Stapleton, Professor and Chair, Department of Pediatrics, Ford/Morgan Endowed Chair in Pediatrics, University of Washington, Seattle, WA

This session is intended to provide trainees and junior faculty with optimistic, yet realistic, insights about career opportunities in pediatric nephrology and appropriate preparation for these careers. Career opportunities, both within and outside of academic departments, will be discussed. Faculty tracks and the perspective of department chairs about these tracks also will be addressed. Topics will include how to choose the appropriate academic position for one’s interests and talents as well as balancing career objectives with personal and family goals.

Target Audience: Trainee, junior faculty.
 

8:00am–10:00am
5110A—Glomerulonephritis in 2005
ASPN Symposium
Chair: John Foreman, Duke University Medical Center, Durham, NC

Glomerulonephritis encompasses a multitude of inflammatory diseases that threaten to impair glomerular filtration. This symposium will review our current understanding of the pathogenetic mechanisms involved, emphasizing etiologic events and the role of individual cells types in determining the clinical and morphologic consequences of immune injury to the glomerulus. New concepts in vasculitis, especially that associated with antineutrophil cytoplasmic antibodies and IgA nephropathy, will be discussed with regard to how these concepts are leading to new therapies. Finally, a number of novel therapies to retard progressive loss of renal function are under intensive investigation. These will be related to both animal models and the results of human trials.

Target Audience: Nephrologists, rheumatologists, and others interested in the care of patients with glomerulonephritis and autoimmune disorders.

Cellular and Molecular Pathology of Glomerulonephritis
William Couser, University of Washington, Woodinville, WA

IgA Nephrology
Robert J. Wyatt, University of Tennessee Memphis, Memphis, TN

New Therapies in Vasculitic Glomerulonephritis
Ronald Falk, University of North Carolina, Chapel Hill, NC

Anti-fibrotic Therapies in the Prevention of Progression of Chronic Glomerulonephritis
Jeffrey Kopp, NIDDK, Bethesda, MD

Supported by the Kidney and Urology Foundation of America (KUFA)
 

11:45pm–1:45pm
Poster Session II
PAS Original Science Abstracts - Poster Session

Nephrology:
5430—Glomerular Diseases/Nephrotic Syndrome: Experimental
5431—Glomerular Diseases/Nephrotic Syndrome: Clinical
5432—Acute Renal Failure
5433—Transplant
5434—Renal Genetics
 

2:00pm–4:00pm
5520—Consequences of Metabolic Syndrome in Children: Hypertension, Diabetes and Renal Disease
PAS/ASPN/IPHA/LWPES Topic Symposium
Chairs: Joseph Flynn, Montefiore Medical Center, Bronx, NY; and Henry Anhalt, Saint Barnabas Medical Center, Livingston, NJ

The incidence of the metabolic syndrome and of type 2 diabetes mellitus (T2DM) is now exploding in children as a consequence of the obesity epidemic. These children may be at significant risk of target-organ damage, including hypertension, atherosclerosis and diabetic nephropathy. This symposium will examine key aspects of this epidemic, with special focus on the pathogenesis of the target-organ effects of the metabolic syndrome in the young.

Target Audience: Any physician who cares for children with obesity, diabetes or their consequences—pediatricians, pediatric cardiologists, pediatric endocrinologists, pediatric nephrologists.

Can We Agree on a Definition of the Metabolic Syndrome in Children?
Sonia K. Caprio, Yale University School of Medicine, New Haven, CT

Pathogenesis of Structural Vascular Changes in Patients with Hypertension and the Metabolic Syndrome
Albert P. Rocchini, University of Michigan Health Center, Ann Arbor, MI

Diabetic Nephropathy in Patients with Type 1 and Type 2 Diabetes
Kumar Sharma, Jefferson Medical College, Philadelphia, PA

Mechanisms of Diabetic Nephropathy: Insights from Genomics/Proteomics
Erwin Bottinger, Mount Sinai School of Medicine, New York, NY

Sponsored jointly by the American Society of Pediatric Nephrology, International Pediatric Hypertension Association, Lawson Wilkins Pediatric Endocrine Society and the Pediatric Academic Societies
 

4:15pm–6:15pm
5742—Nephrology
PAS/ASPN Original Science Abstracts - Platform Session

Monday, MAY 16

8:00am–10:00am
6110A—Acute Renal Failure: Today and Tomorrow from the Bench and the Bedside
ASPN Symposium
Chairs: Lisa Satlin, Mt. Sinai School of Medicine, New York, NY; and Michael Somers, Children's Hospital, Boston, MA

Advances in the care of critically ill children have contributed to an increased likelihood of clinicians facing children with acute renal failure (ARF), underscoring the need to better delineate the alterations in normal renal cellular and vascular homeostasis that underlie such dysfunction. This understanding should allow for the development of optimal strategies to prevent and treat the immediate and long-term consequences of ARF. In this session, there will be initial focus on the microvascular alterations that occur during and following renal ischemia, including the interaction between the white blood cell and the endothelial cell. Next, we will transition to the role of changes in vascular microstructure as a contributing factor in the development of chronic renal failure after an acute insult. An update on the epidemiology of pediatric ARF and what is currently understood regarding the timing and outcome of specific clinical interventions will be discussed, with a special emphasis on the continuous modalities of renal replacement therapy and their impact on both the approach to pediatric ARF and outcome. The symposium will conclude with a look at the potential role of stem cell therapy in future therapeutic modalities.

Target Audience: Clinicians and researchers interested in gaining an update on suspected pathophysiologic mechanisms of acute renal failure and the role these alterations may play in the potential development of long-term renal dysfunction.

New Insights into the Molecular and Cellular Pathophysiology of Acute Renal Failure
Bruce Molitoris, University of Indiana, Indianapolis, IN

Chronic Sequelae of ARF
David Basile, Medical College of Wisconsin, Milwaukee, WI

New Clinical Interventions in ARF
Michael Somers, Harvard University, Boston, MA

Novel Therapies for ARF: Stem Cells
Fangming Lin, University of Texas Southwestern Medical Center, Dallas, TX
 

10:15am–12:00pm
6300—SPR Presidential Plenary and Awards
SPR Presidential Plenary

Introduction
Lisa M. Guay-Woodford, University of Alabama at Birmingham, Birmingham, AL

Richard D. Rowe Awardee
Vidu Garg, University of Texas Southwestern Medical School, Dallas, TX

Richard D. Rowe Award Honorable Mention
Conrad L. Epting, University of California, San Francisco
Stephanie Marie Ware, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Maureen Andrew Mentor Awardee
Edward R.B. McCabe, Mattel Children's Hospital at UCLA, Los Angeles, CA

David G. Nathan Awardee
Mwe Mwe Chao,

Douglas K. Richardson Awardee
Maureen Hack, Case Western Reserve University, Cleveland, OH

SPR Distinguished Service Award
Samuel Hawgood, University of California Medical Center, San Francisco, CA

E. Mead Johnson Awardees

Elizabeth C. Engle, Children's Hospital, Boston, MA

Gene Therapy for Inherited Lung Disease
Terence R. Flotte, University of Florida, Gainesville, FL

SPR Presidential Address
Lisa M. Guay-Woodford, University of Alabama at Birmingham, Birmingham, AL

*The E. Mead Johnson Awards are supported by an educational grant from Mead Johnson Nutritionals
 

12:30pm–3:00pm
6450A—ASPN Presidential Address and Awards Luncheon
ASPN Presidential Plenary

3:30pm–5:30pm
6780A—The Next Steps in Pediatric Renal Transplantation
ASPN Symposium
Chairs: Richard N. Fine, SUNY at Stony Brook, Stony Brook, NY; and Bruce Morgenstern, Mayo Clinic, Rochester, MN; and Ruth McDonald, Children's Hospital and Regional Medical Center, Seattle, WA

Current immunosuppressive regimens have led to remarkable success rates for Pediatric renal transplant patients. The science of the field is now poised to move to the next level. Improved knowledge of allograft recognition and drug toxicities and interactions offers opportunities to maintain excellent outcomes while simultaneously minimizing toxicities and morbidities. Additionally, demand for organs has increased, as has the number of children at high immunological risk who are awaiting transplant. This symposium will review the state of the art of minimization protocols and new immunosuppressive agents, offering ideas as to what options appear to be best. It will explore expanded donor pools and the impact on children awaiting organs from deceased donors and also explore new approaches to the child at high immunologic risk. The symposium will also review how genomics can be brought from the bench to the bedside in the management of children in the post-transplant period.

Target Audience: Clinicians, scientists and trainees involved in renal transplantation, transplantation of other solid organs, and blood and marrow transplant.

Setting the Stage: Where Do We Go Next?
Richard N. Fine, SUNY at Stony Brook, Stony Brook, NY
Bruce Z. Morgenstern, Mayo Clinic, Rochester, MN

The Success of Minimization Protocols: How Will They Compare with Immunosuppressive Agents on the Horizon?
William E. Harmon, Children's Hospital, Boston, MA

Extended Donor Criteria and the Pediatric Recipient: How To Optimize the Deceased Donor List for the Benefit of Our Patients
Ruth McDonald, Children's Hospital and Regional Medical Center, Seattle, WA

Microarrays and Patient Monitoring: When Will They Be at the Bedside?
Minnie Sarwal, Stanford University Medical Center, Stanford, CA

New Approaches to the Highly Sensitized Recipient: What Does the Patient Really Need?
James Gloor, Mayo Clinic, Rochester, MN

Sponsored jointly by the American Society of Transplantation and the American Society of Pediatric Nephorlogy
 

Tuesday, MAY 17

8:00am–10:00am
7102—Transitioning Complex Pediatric Patients to Adult Care
PAS/ASPN/LWPES Hot Topic
Chair: Sandra L. Watkins, University of Washington, Seattle, WA

Transitions are a part of everyone's life experience. Most young people with special health care needs and disabilities (SHCN/D) become independent members of adult society, but some need deliberate guidance and support. With increasing success in reducing the mortality of once devastating pediatric diseases, the latter group is growing in number. A new consensus statement from the American Academy of Pediatrics and the U.S. Federal Government (Healthy People 2010) has focused attention on the need to assist young people with SHCN/D in attaining their potential in adulthood. This symposium will discuss the growing number of young people with SHCN/D and present approaches for effecting these transitions.  Specific disease-related examples will be used to highlight the issues, the barriers and the key elements of successful programs that transition patients from pediatric care to the adult system.

All Grown Up and Wondering What To Do: Transitioning Complex Pediatric Patients to Adult Care
Patience H. White, George Washington University School of Medicine, Washington, DC

Transition Best Practices
Cecily L. Betz, University Center For Excellence in Development Disabilities, Children's Hospital Los Angeles, CA

Transition to Adult Care in the Nephrology Population–Renal Failure or Success
Maria Ferris, University of North Carolina-Chapel Hill, NC

Training and Workforce Issues for Successful Transition
Roberta G. Williams, University of Southern California, Los Angeles, CA

Discussion

Sponsored jointly by the American Society of Pediatric Nephrology, Lawson Wilkins Pediatric Endocrine Society and the Pediatric Academic Societies
 

1:45pm–3:45pm
7601—New Therapeutic Strategies for Classical Pediatric Diseases
PAS Hot Topic
Chairs: David Cornfield, University of Minnesota School of Medicine, Minneapolis, MN; and Nina F. Schor, Children's Hospital of Pittsburgh, Pittsburgh, PA

The pathogenesis of numerous single-gene disorders has been effectively delineated. However, the application of this knowledge to patient care has lagged far behind. This symposium will present recent progress made in the development of therapeutic strategies for four classical pediatric disorders. First, novel genetic therapies for hematologic diseases will be discussed. Second, interventions that reverse the key abnormalities in signal transduction underlying autosomal dominant polycystic kidney disease, a leading cause of end-stage renal disease, will be presented. Third, we will discuss a treatment strategy that normalizes the intracellular processing and function of the mutated cystic fibrosis transmembrane conductance regulator (CFTR), which underlies the majority of cases of CF. Fourth, pharmacologic strategies against muscular dystrophy will be presented. These four innovative approaches provide great hope for patients suffering from these disorders, and they serve as exciting examples of potential means to combat other devastating pediatric conditions.

Target Audience: Scientists and clinicians involved with the development of new therapeutic strategies for a variety of childhood disorders.

Embryonic Globins as Therapeutic Agents for Hemoglobinopathies and Thalassemias
J. Eric Russell, The Children's Hospital of Philadelphia, Philadelphia, PA

Novel Therapies for Renal Cystic Diseases
Vicente E. Torres, Mayo Clinic, Rochester, MN

Treatment of Cystic Fibrosis with Curcumin
Marie E. Egan, Yale University School of Medicine, New Haven, CT

Pharmacologic Strategies Against Muscular Dystrophy
Tejvir S. Khurana, University of Pennsylvania School of Medicine, Philadelphia, PA

PDF Files require the free Acrobat Reader. Click here to download a copy.